NO994906L - GnRH antagonister som er modifisert i stillinger 5 og 6 - Google Patents

GnRH antagonister som er modifisert i stillinger 5 og 6

Info

Publication number
NO994906L
NO994906L NO994906A NO994906A NO994906L NO 994906 L NO994906 L NO 994906L NO 994906 A NO994906 A NO 994906A NO 994906 A NO994906 A NO 994906A NO 994906 L NO994906 L NO 994906L
Authority
NO
Norway
Prior art keywords
positions
gnrh antagonists
modified
antagonists modified
gnrh
Prior art date
Application number
NO994906A
Other languages
English (en)
Other versions
NO994906D0 (no
NO324991B1 (no
Inventor
Graeme Semple
Guangcheng Jiang
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25273352&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO994906(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of NO994906D0 publication Critical patent/NO994906D0/no
Publication of NO994906L publication Critical patent/NO994906L/no
Publication of NO324991B1 publication Critical patent/NO324991B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/11—Gonadotropin; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
NO19994906A 1997-04-11 1999-10-08 GnRH antagonistpeptid samt farmasoytisk preparat inneholdende det samme. NO324991B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/837,042 US5925730A (en) 1997-04-11 1997-04-11 GnRH antagonists
PCT/US1998/007438 WO1998046634A1 (en) 1997-04-11 1998-04-13 GnRH ANTAGONISTS BEING MODIFIED IN POSITIONS 5 AND 6

Publications (3)

Publication Number Publication Date
NO994906D0 NO994906D0 (no) 1999-10-08
NO994906L true NO994906L (no) 1999-12-13
NO324991B1 NO324991B1 (no) 2008-01-14

Family

ID=25273352

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19994906A NO324991B1 (no) 1997-04-11 1999-10-08 GnRH antagonistpeptid samt farmasoytisk preparat inneholdende det samme.
NO2009016C NO2009016I2 (no) 1997-04-11 2009-07-23 D-alaninamid, N-acetyl-3(2-naftalenyl)-D-alanyl-4-klor-D-fenylalanyl-3(3-pyridinyl)-D-alanyl-L-seryl-4[[[(4S)-heksahydro-2,6-diokso-4-pyrimidinyl]karbonyl]amino]-L-fenylalanyl-4[(aminokarbonyl)amino]-D-fenvlalanvl-L-leucvl-N6(1-metvletvl-L-1vsvl-L-nrolvl-

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2009016C NO2009016I2 (no) 1997-04-11 2009-07-23 D-alaninamid, N-acetyl-3(2-naftalenyl)-D-alanyl-4-klor-D-fenylalanyl-3(3-pyridinyl)-D-alanyl-L-seryl-4[[[(4S)-heksahydro-2,6-diokso-4-pyrimidinyl]karbonyl]amino]-L-fenylalanyl-4[(aminokarbonyl)amino]-D-fenvlalanvl-L-leucvl-N6(1-metvletvl-L-1vsvl-L-nrolvl-

Country Status (37)

Country Link
US (2) US5925730A (no)
EP (1) EP1003774B1 (no)
JP (2) JP4249806B2 (no)
KR (1) KR100519421B1 (no)
CN (1) CN1230442C (no)
AR (1) AR011217A1 (no)
AT (1) ATE319736T1 (no)
AU (1) AU728642B2 (no)
BR (1) BR9808523B1 (no)
CA (1) CA2286190C (no)
CY (2) CY1108063T1 (no)
CZ (1) CZ299097B6 (no)
DE (2) DE122009000033I2 (no)
DK (1) DK1003774T3 (no)
EE (1) EE03974B1 (no)
ES (1) ES2260833T3 (no)
FR (1) FR09C0028I2 (no)
HK (1) HK1025104A1 (no)
HR (1) HRP980197B1 (no)
HU (1) HU224836B1 (no)
IL (1) IL132303A0 (no)
LU (1) LU91585I2 (no)
MY (1) MY114811A (no)
NL (1) NL300395I2 (no)
NO (2) NO324991B1 (no)
NZ (1) NZ500142A (no)
PL (1) PL194509B1 (no)
PT (1) PT1003774E (no)
RU (1) RU2199549C2 (no)
SI (1) SI1003774T1 (no)
SK (1) SK285381B6 (no)
TR (1) TR199902956T2 (no)
TW (1) TW505658B (no)
UA (1) UA58547C2 (no)
UY (1) UY24958A1 (no)
WO (1) WO1998046634A1 (no)
ZA (1) ZA983062B (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
US5925730A (en) * 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
AU1590699A (en) * 1997-11-20 1999-06-15 Ortho-Mcneil Pharmaceutical, Inc. Liquid phase process for the preparation of gnrh peptides
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
IL147138A0 (en) * 2001-12-17 2002-08-14 Yeda Res & Dev Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation
DE20321887U1 (de) 2003-11-10 2012-01-20 Allergan, Inc. Arzneimittel umfassend niedrige Dosierungen von Desmopressin
EP1689419A4 (en) 2003-11-10 2009-01-14 Reprise Biopharmaceutics Llc PHARMACEUTICAL COMPOSITIONS WITH LOW DOSES OF DESMOPRESSIN
CN101037472B (zh) * 2006-03-14 2013-03-27 中国人民解放军军事医学科学院毒物药物研究所 具有低组胺释放作用的促黄体生成素释放激素拮抗剂
ES2426445T3 (es) * 2006-04-07 2013-10-23 Merrion Research Iii Limited Forma de dosificación oral sólida que contiene un potenciador
JOP20090061B1 (ar) 2008-02-11 2021-08-17 Ferring Int Center Sa طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
US8999383B2 (en) * 2008-05-07 2015-04-07 Merrion Research Iii Limited Compositions of GnRH related compounds and processes of preparation
CA2751854A1 (en) * 2009-02-25 2010-09-02 Merrion Research Iii Limited Composition and drug delivery of bisphosphonates
US8828938B2 (en) * 2009-04-24 2014-09-09 Polypeptide Laboratories A/S Method for the manufacture of degarelix
MX2011011431A (es) * 2009-05-01 2012-02-23 Ferring Bv Composicion para el tratamiento de cancer de prostata.
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
WO2011066386A1 (en) 2009-11-25 2011-06-03 Novetide, Ltd. Process for production of degarelix
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US9089484B2 (en) * 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
ES2617336T3 (es) 2010-10-27 2017-06-16 Ferring B.V. Procedimiento para la fabricación de degarelix y sus productos intermedios
ES2703499T3 (es) 2010-12-22 2019-03-11 Salk Inst Biological Studies Péptidos antagonistas de CRF cíclicos
WO2012094598A2 (en) 2011-01-07 2012-07-12 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
WO2013104745A1 (en) 2012-01-13 2013-07-18 Ferring Bv Pharmaceutical composition
WO2013178788A2 (en) 2012-06-01 2013-12-05 Ferring B.V. Manufacture of degarelix
US10265384B2 (en) 2015-01-29 2019-04-23 Novo Nordisk A/S Tablets comprising GLP-1 agonist and enteric coating
EP3981781A1 (en) 2015-12-17 2022-04-13 Fresenius Kabi iPSUM S.r.l. Process for the manufacture of degarelix and its intermediates
CN107778355B (zh) * 2016-08-25 2021-04-20 成都圣诺生物制药有限公司 一种合成西曲瑞克的方法
WO2019110688A1 (en) 2017-12-05 2019-06-13 Ferring B.V. A composition comprising degarelix for use in the treatment of breast cancer
US20220267347A1 (en) 2019-07-29 2022-08-25 Sunshine Lake Pharma Co., Ltd. Substituted pyrimidinedione compounds and uses thereof
US11332495B2 (en) 2019-09-21 2022-05-17 RK Pharma Solutions LLC Process for the preparation of Degarelix acetate and Degarelix acetate-mannitol premix
CN114456236A (zh) * 2020-11-09 2022-05-10 深圳市健翔生物制药有限公司 一种地加瑞克乙酰化杂质的制备方法
CN118159541A (zh) 2021-11-01 2024-06-07 山东绿叶制药有限公司 促性腺素释放激素拮抗剂及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4547370A (en) * 1983-11-29 1985-10-15 The Salk Institute For Biological Studies GnRH Antagonists
US4508921A (en) * 1984-06-28 1985-04-02 Merck & Co., Inc. Process for preparation of alpha-alkyl amino acids
US5073624A (en) * 1985-04-09 1991-12-17 Administrators Of The Tulane Educational Fund Therapeutic decapeptides
US4866160A (en) * 1985-04-09 1989-09-12 The Administrators Of The Tulane Educational Fund Therapeutic decapeptides
US4800191A (en) * 1987-07-17 1989-01-24 Schally Andrew Victor LHRH antagonists
US4935491A (en) * 1987-08-24 1990-06-19 Board Of Regents, The University Of Texas System Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine
US5171835A (en) * 1988-10-21 1992-12-15 The Administrators Of The Tulane Educational Fund LHRH antagonists
US5296468A (en) * 1989-10-30 1994-03-22 The Salk Institute For Biological Studies GnRH analogs
JP2719233B2 (ja) * 1991-04-25 1998-02-25 デゲンギ，ロマノ 黄体形成ホルモン放出ホルモン拮抗ペプチド
JP3568952B2 (ja) * 1992-12-18 2004-09-22 アボット・ラボラトリーズ ５位及び６位に修飾アミノアシル残基を有するｌｈｒｈ拮抗薬
IL108509A0 (en) * 1993-02-22 1994-05-30 Salk Inst For Biological Studi GnRH antagonist peptides
US5506207A (en) * 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5843901A (en) * 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5925730A (en) * 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists

Also Published As

Publication number Publication date
CN1230442C (zh) 2005-12-07
JP3645255B1 (ja) 2005-05-11
US6214798B1 (en) 2001-04-10
BR9808523B1 (pt) 2010-02-09
CY2009008I1 (el) 2012-01-25
CZ358699A3 (cs) 2000-06-14
JP4249806B2 (ja) 2009-04-08
AU6969898A (en) 1998-11-11
RU2199549C2 (ru) 2003-02-27
AR011217A1 (es) 2000-08-02
JP2001523229A (ja) 2001-11-20
HUP0002704A2 (hu) 2000-12-28
NO994906D0 (no) 1999-10-08
DK1003774T3 (da) 2006-07-03
PL194509B1 (pl) 2007-06-29
UA58547C2 (uk) 2003-08-15
PL336213A1 (en) 2000-06-05
NO2009016I2 (no) 2014-08-25
SK285381B6 (sk) 2006-12-07
US5925730A (en) 1999-07-20
NZ500142A (en) 2001-10-26
KR20010006233A (ko) 2001-01-26
HRP980197A2 (en) 1999-02-28
FR09C0028I2 (fr) 2010-06-11
NL300395I2 (nl) 2010-01-04
EE03974B1 (et) 2003-02-17
DE122009000033I1 (de) 2009-09-17
CY1108063T1 (el) 2012-01-25
CY2009008I2 (el) 2012-01-25
BR9808523A (pt) 2000-05-23
LU91585I2 (fr) 2009-09-17
TR199902956T2 (xx) 2000-08-21
ZA983062B (en) 1998-10-20
FR09C0028I1 (no) 2009-09-25
KR100519421B1 (ko) 2005-10-06
EP1003774A1 (en) 2000-05-31
NL300395I1 (nl) 2009-09-01
HRP980197B1 (en) 2002-08-31
HUP0002704A3 (en) 2003-08-28
SK139699A3 (en) 2000-11-07
IL132303A0 (en) 2001-03-19
NO324991B1 (no) 2008-01-14
AU728642B2 (en) 2001-01-11
MY114811A (en) 2003-01-31
CA2286190C (en) 2007-01-09
ES2260833T3 (es) 2006-11-01
WO1998046634A1 (en) 1998-10-22
EP1003774B1 (en) 2006-03-08
NO2009016I1 (no) 2009-08-10
CZ299097B6 (cs) 2008-04-23
ATE319736T1 (de) 2006-03-15
HK1025104A1 (en) 2000-11-03
TW505658B (en) 2002-10-11
CA2286190A1 (en) 1998-10-22
SI1003774T1 (sl) 2006-08-31
DE122009000033I2 (de) 2011-07-21
DE69833751T2 (de) 2006-11-09
PT1003774E (pt) 2006-05-31
HU224836B1 (en) 2006-03-28
EE9900479A (et) 2000-06-15
CN1259959A (zh) 2000-07-12
JP2005120101A (ja) 2005-05-12
UY24958A1 (es) 2001-03-16
DE69833751D1 (de) 2006-05-04

Similar Documents

Publication Publication Date Title
NO994906D0 (no) GnRH antagonister som er modifisert i stillinger 5 og 6
DE59713038D1 (de) Streptavidinmuteine
DK0796846T3 (da) 2-Aryl-substituerede pyridiner
DK0832061T3 (da) Benzamidderivater og anvendelse deraf som vasopressin-antagonister
DK0815861T3 (da) Sulfonamider og anvendelse deraf
NO996108D0 (no) 9-oksinerytromycinderivater
ID24669A (id) Turunan-turunan dolastatin 15
NO20004274D0 (no) Proteaseaktivert reseptor 4 og anvendelse derav
ATE227724T1 (de) Muscarinagonisten und antagonisten
DE59707485D1 (de) Kontaktstift
DE59808091D1 (de) Ventilanordnung
PT811593E (pt) Agentes insecticidas e acaricidas 1,4-diaril-2-fluor-2-buteno
DE59801426D1 (de) Ventilanordnung
PT964867E (pt) Antagonistas da taquicinima
DE59800655D1 (de) Ventilanordnung
BR9806041A (pt) V lvula
FI972010A0 (fi) Arrangemang i en borrningsanordning
KR970702876A (ko) 뉴로키닌 길항제(Neurokinine (tachykinine) antagonists)
FI974109A0 (fi) Arrangemang i en lindningsanordning
DE69800191D1 (de) Ventilanordnung
DE29712172U1 (de) Ventilanordnung
DK0707579T3 (da) Piperidinylsubstituerede methanoanthracener som D1/D2-antagonister og 5 HT2-serotanin-antagonister
FI980691A0 (fi) Xylitoltillsats i roektobak
FI972291A0 (fi) Arrangemang i glasboejningsugn
FI970497A0 (fi) Arrangemang foer raeddningsvaeg i en byggnad med flera vaoningar

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: OSLO PATENTKONTOR AS, POSTBOKS 7007 MAJORSTUA, 030

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: DEGARELIX EVENTUELT I FORM AV ET FARMASOYTISK AKSEPTABELT SALT SA SOM ACETATET; REG. NO/DATE: EU108504001 20090217

Spc suppl protection certif: 2009016

Filing date: 20090723

Extension date: 20230413

MK1K Patent expired
SPCX Expiry of an spc

Spc suppl protection certif: 2009016

Expiry date: 20230504